Shunji Fujimori, Tsuguhiko Seo, Katya Gudis, Akihito Ehara, Tsuyoshi Kobayashi, Keigo Mitsui, Masaoki Yonezawa, Shu Tanaka, Atsushi Tatsuguchi, Choitsu Sakamoto
Journal: Gastrointestinal endoscopy 2009;69(7):1339-46
PMID: 19243767
BACKGROUND
There is no known preventive agent against nonsteroidal anti-inflammatory drug (NSAID) induced small-intestinal injury.
OBJECTIVE
To evaluate by capsule endoscopy whether coadministration of prostaglandin (PG) can prevent small-intestinal damage induced by short-term NSAID treatment.
DESIGN
Single-blind, randomized, controlled trial.
SETTING
All procedures were performed at Nippon Medical School.
SUBJECTS
Thirty-four healthy male volunteers.
METHODS
All subjects were randomly assigned to 2 groups: an NSAID-control group, who underwent NSAID (diclofenac sodium, 25 mg 3 times daily) and omeprazole (20 mg once daily) treatment, and an NSAID-PG group, who received PG (misoprostol, 200 microg 3 times daily) in addition to the same NSAID-omeprazole treatment. Eligible subjects, 15 per group, underwent capsule endoscopy before and 14 days after treatment.
MAIN OUTCOME MEASUREMENTS
The number of mucosal breaks at capsule endoscopy.
RESULTS
NSAID treatment significantly increased the mean (SD) number of mucosal breaks per subject, from a basal level of 0.1 +/- 0.3 up to 2.9 +/- 6.3 lesions in the NSAID-control group (P = .012). In contrast, there was no significant change in the mean number of mucosal breaks before and after PG cotreatment (P = 0.42). Thus, the mean number of posttreatment mucosal breaks per subject was significantly higher in the NSAID-control group than in the NSAID-PG group (P = .028). There was a significant increase in the percentage of subjects in the NSAID-control group, with at least 1 mucosal break after treatment (from 6.7% to 53.3%), whereas there was no change in the incidence of mucosal breaks in the NSAID-PG group, which remained at 13.3%. (P = .002).
LIMITATIONS
Single-center, open-label study.
CONCLUSIONS
PG cotherapy reduced the incidence of small-intestinal lesions induced by a 2-week administration of diclofenac sodium.
© Copyright 2026, Nutrition Evidence
We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.